Artelo Biosciences (ARTL) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Artelo Biosciences is the larger company by market cap ($1.8 million vs $138,068), about 12.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTL | MDCX |
|---|---|---|
| Share price | $3.26 | $0.0921 |
| Market cap | $1.79M | $138.07K |
| 1-day change | -3.26% | -9.62% |
| YTD return | — | -93.98% |
| 1-year return | — | -96.33% |
| EPS (TTM) | $-136.26 | $-119.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $179.19 | $139.00 |
| 52-week low | $3.19 | $0.084 |
| Distance from 52-week high | -98.18% | -99.93% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +4785.99% |
| Average volume | 480.92K | 92.96K |
| Shares outstanding | 547.77K | 1.50M |
| Employees | 7 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Artelo Biosciences is about 12.9 times larger than Medicus Pharma by market value ($1.79M vs $138.07K).
About Artelo Biosciences
ARTL stock →Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
ARTL vs MDCX FAQ
Which is bigger, Artelo Biosciences or Medicus Pharma?
Artelo Biosciences (ARTL) is larger, with a market capitalization of $1.79M compared with $138.07K for Medicus Pharma (MDCX).
Are Artelo Biosciences and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.